David A. DeGoey

AbbVie (United States) — United States

Medicine · Health Sciences

16h-index1.4kcitations44works13.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(23), Hepatitis C virus research(13), Computational Drug Discovery Methods(9), HIV Research and Treatment(8), Chemical Synthesis and Analysis(5)

Publications44 total

Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding
iScience·2025· 1 citedOpen Access
Explainable Machine Learning for ETR and Drug Chameleonicity
Journal of Medicinal Chemistry·2025· 2 cited
Inhibition of Dimeric SARS-CoV-2 Mpro Displays Positive Cooperativity and a Mixture of Covalent and Non-Covalent Binding
SSRN Electronic Journal·2025Open Access
Development of a sensitive high-throughput enzymatic assay capable of measuring sub-nanomolar inhibitors of SARS-CoV2 Mpro
SLAS DISCOVERY·2024· 1 citedOpen Access
Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
Journal of Medicinal Chemistry·2024· 62 cited
Discovery and Development of First and Second Generation of NS5A Inhibitors Ombitasvir and Pibrentasvir
Elsevier eBooks·2023
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
Viruses·2022· 97 citedOpen Access
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain
Bioorganic & Medicinal Chemistry·2022· 3 citedOpen Access
Implications of the Conformationally Flexible, Macrocyclic Structure of the First-Generation, Direct-Acting Anti-Viral Paritaprevir on Its Solid Form Complexity and Chameleonic Behavior
Journal of the American Chemical Society·2021· 50 cited
Global Analysis of Models for Predicting Human Absorption: QSAR, <i>In Vitro</i> , and Preclinical Models
Journal of Medicinal Chemistry·2021· 32 cited
Desymmetrization of Pibrentasvir for Efficient Prodrug Synthesis
2021Open Access
Desymmetrization of Pibrentasvir for Efficient Prodrug Synthesis
2021· 1 citedOpen Access
Drug Discovery Beyond the Rule of Five
Burger's Medicinal Chemistry and Drug Discovery·2021· 2 cited
Desymmetrization of pibrentasvir for efficient prodrug synthesis
Chemical Science·2021· 6 citedOpen Access
Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)
Journal of Medicinal Chemistry·2020· 19 cited
CCDC 2007621: Experimental Crystal Structure Determination
The Cambridge Structural Database·2020Open Access
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors
Bioorganic & Medicinal Chemistry Letters·2020· 4 citedOpen Access
Synthesis and evaluation of 2′-dihalo ribonucleotide prodrugs with activity against hepatitis C virus
Bioorganic & Medicinal Chemistry·2019· 5 cited
HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments
Topics in medicinal chemistry·2019· 2 cited
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection
Journal of Medicinal Chemistry·2017· 364 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

John T. Randolph(16), Larry L. Klein(12), David J. Grampovnik(11), Dale J. Kempf(11), Warren M. Kati(8), Akhteruzzaman Molla(8), William J. Flosi(8), Tatyana Dekhtyar(8), Clinton M. Yeung(7), Kennan C. Marsh(7), Eric A. Voight(7), Preethi Krishnan(6), Rolf Wagner(6), Hui-Ju Chen(5), A. Chris Krueger(5), Daniel A.J. Bow(5), Philip B. Cox(4), Mark A. Matulenko(4), Stephen N. Greszler(4), DeAnne Stolarik(4)